HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and hepatic decompensation, according to a study published ...

The FDA has issued a complete response letter for rivoceranib plus camrelizumab as a first-line treatment for unresectable ...

A research team led by Prof. Sun Cheng from the University of Science and Technology of China (USTC), in collaboration with ...

Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most ...

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and ...

Advanced-stage hepatocellular carcinoma is currently treated with various anti-PD-(L)1 antibody-containing regimens. Now, a triplet combining the anti-TIGIT antibody tiragolumab with one of these ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Abbreviations: AFP, alpha-fetoprotein; CIK, cytokine-induced killer; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; HAIC, hepatic arterial infusion chemotherapy ...

Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. In November 2021, the U.S. Food and Drug Administration ("FDA”) granted ...

Furthermore, a supplemental New Drug Application (sNDA) for penpulimab in combination with anlotinib for first-line treatment of advanced hepatocellular carcinoma (HCC) is currently under review.

Durvalumab in combination with Tremelimumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC), it added. The receipt of this permission paves way for the ...